With less than 10% of investigational products making it to post-marketing surveillance during clinical trials, it is imperative to build a statistical analysis plan for any clinical study, Dr. Cheng brought to HMC of extensive and flexible biostatistical capabilities for different phases of clinical trials. Under his guidance, each analysis is custom built based on our client’s clinical research goals, and performed to ICH-GCP standards, and uses the latest, best-in-class statistical software.
Dr. Cheng’s extensive experience in clinical data analysis allows HMC to provide an individualized service offering for our clients in each clinical trial, regardless of the complexity of the biostatistical needs, from study design, to sample size calculation, to protocol development & review, to randomization, and statistical analysis plans, analysis and Interpretation, data presentation and reports. Biostatistician is the key driver behind trial design, it’s one of the key components of clinical trial design, for many studies, regulatory agencies review the statistical analysis plan (SAP) as part of the trial design review.
Dr. Cheng obtained his Ph.D. in Pharmaceutical Science from University of Arizona
Biography and role are preserved from the HMC website ↗.
Back to our team